Safety data sheet
Standardized safety protocols and material specifications for professional use.
Certificate of Analysis
Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-semaglutide-10mg
Semaglutide (10mg)
Ultra High >99.5% Purity
Authorized Resellers
Available through our trusted partners
123peptide.com
Netherlands · Europe
local_shipping2-3 Business Days
Depeptidenwinkel.com
Netherlands · Europe
local_shipping2-3 Business Days
Scientific Background
This 10mg vial offers greater flexibility for maintenance dosing or accelerated titration in weight management protocols. With its proven track record in clinical trials, semaglutide stands as a cornerstone for those seeking sustainable fat loss.
Semaglutide is a long-acting synthetic analog of glucagon-like peptide-1 (GLP-1), designed to mimic the body's natural hormone that regulates appetite, insulin secretion, and glucose metabolism.
Experience the power of GLP-1 activation to curb hunger and boost metabolism. Semaglutide binds to GLP-1 receptors in the brain and gut, reducing hunger signals, slowing gastric emptying, and enhancing insulin release in a glucose-dependent manner. Its extended half-life of approximately 7 days allows for convenient once-weekly administration.
Intended Research Use
- Suppresses appetite and promotes satiety
- Enhances insulin sensitivity and glycemic control
- Supports significant weight reduction
- Improves cardiovascular and metabolic markers
- GLP-1 receptor binding and metabolic pathway research
menu_bookScientific Publications
N Engl J Med (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/33567185/
JAMA (2021)
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/33625476/
JAMA (2021)
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/33625476/
Clinical Evidence: In phase 3 clinical trials, semaglutide at maintenance doses led to 10–15% average body weight loss over 68 weeks. Compared to tirzepatide (GLP-1/GIP dual agonist), semaglutide offers slightly less aggressive weight loss (10–15% vs 15–21%) but with a more favorable tolerability profile for many users.
FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.
Possible stacks with other peptides
Synergistic combinations for enhanced research outcomes
Clinical research suggests combining Semaglutide with complementary peptides can enhance weight management outcomes. These combinations target multiple metabolic pathways for amplified fat-burning and appetite control effects.
Cagrilintide (5mg vial)
arrow_forwardmyo-cagrilintide-5mg
Combines GLP-1 with amylin analog for enhanced satiety and superior weight loss synergy (CagriSema approach).
AOD-9604 (5mg vial)
arrow_forwardmyo-hgh-fragment-aod-9604-5mg
Pairs appetite control with targeted fat metabolism for localized contouring support.
Retatrutide (10mg vial)
arrow_forwardmyo-retatrutide-10mg
Adds GIP/glucagon activation to semaglutide's GLP-1 for amplified fat-burning and energy effects.
CagriSema (Semaglutide + Cagrilintide) (5mg + 5mg vial)
arrow_forwardmyo-semaglutide-plus-cagrilintide-5mg-5mg
Semaglutide combined with cagrilintide's amylin action for superior dual-mechanism weight loss — the logical progression from standalone Semaglutide research.
Tirzepatide 10mg (10mg vial)
arrow_forwardmyo-tirzepatide-10mg
Dual GLP-1/GIP agonist with superior glycemic control and higher weight loss ceiling — compared with Semaglutide in head-to-head clinical research.
Cycling Note: Continue for sustained weight loss; clinical trials support 68+ weeks of continuous use for optimal results.
